BACKGROUND:Vitamin D metabolites support innate immune responses to Mycobacterium tuberculosis. Data from phase 3, randomized, controlled trials of vitamin D supplementation to prevent tuberculosis infection are lacking. METHODS: We randomly assigned children who had negative results for M. tuberculosis infection according to the QuantiFERON-TB Gold In-Tube assay (QFT) to receive a weekly oral dose of either 14,000 IU of vitamin D3 or placebo for 3 years. The primary outcome was a positive QFT result at the 3-year follow-up, expressed as a proportion of children. Secondary outcomes included the serum 25-hydroxyvitamin D (25[OH]D) level at the end of the trial and the incidence of tuberculosis disease, acute respiratory infection, and adverse events. RESULTS: A total of 8851 children underwent randomization: 4418 were assigned to the vitamin D group, and 4433 to the placebo group; 95.6% of children had a baseline serum 25(OH)D level of less than 20 ng per milliliter. Among children with a valid QFT result at the end of the trial, the percentage with a positive result was 3.6% (147 of 4074 children) in the vitamin D group and 3.3% (134 of 4043) in the placebo group (adjusted risk ratio, 1.10; 95% confidence interval [CI], 0.87 to 1.38; P = 0.42). The mean 25(OH)D level at the end of the trial was 31.0 ng per milliliter in the vitamin D group and 10.7 ng per milliliter in the placebo group (mean between-group difference, 20.3 ng per milliliter; 95% CI, 19.9 to 20.6). Tuberculosis disease was diagnosed in 21 children in the vitamin D group and in 25 children in the placebo group (adjusted risk ratio, 0.87; 95% CI, 0.49 to 1.55). A total of 29 children in thevitamin D group and 34 in the placebo group were hospitalized for treatment of acute respiratory infection (adjusted risk ratio, 0.86; 95% CI, 0.52 to 1.40). The incidence of adverse events did not differ significantly between the two groups. CONCLUSIONS:Vitamin D supplementation did not result in a lower risk of tuberculosis infection, tuberculosis disease, or acute respiratory infection than placebo among vitamin D-deficient schoolchildren in Mongolia. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT02276755.).
RCT Entities:
BACKGROUND:Vitamin D metabolites support innate immune responses to Mycobacterium tuberculosis. Data from phase 3, randomized, controlled trials of vitamin D supplementation to prevent tuberculosis infection are lacking. METHODS: We randomly assigned children who had negative results for M. tuberculosis infection according to the QuantiFERON-TB Gold In-Tube assay (QFT) to receive a weekly oral dose of either 14,000 IU of vitamin D3 or placebo for 3 years. The primary outcome was a positive QFT result at the 3-year follow-up, expressed as a proportion of children. Secondary outcomes included the serum 25-hydroxyvitamin D (25[OH]D) level at the end of the trial and the incidence of tuberculosis disease, acute respiratory infection, and adverse events. RESULTS: A total of 8851 children underwent randomization: 4418 were assigned to the vitamin D group, and 4433 to the placebo group; 95.6% of children had a baseline serum 25(OH)D level of less than 20 ng per milliliter. Among children with a valid QFT result at the end of the trial, the percentage with a positive result was 3.6% (147 of 4074 children) in the vitamin D group and 3.3% (134 of 4043) in the placebo group (adjusted risk ratio, 1.10; 95% confidence interval [CI], 0.87 to 1.38; P = 0.42). The mean 25(OH)D level at the end of the trial was 31.0 ng per milliliter in the vitamin D group and 10.7 ng per milliliter in the placebo group (mean between-group difference, 20.3 ng per milliliter; 95% CI, 19.9 to 20.6). Tuberculosis disease was diagnosed in 21 children in the vitamin D group and in 25 children in the placebo group (adjusted risk ratio, 0.87; 95% CI, 0.49 to 1.55). A total of 29 children in the vitamin D group and 34 in the placebo group were hospitalized for treatment of acute respiratory infection (adjusted risk ratio, 0.86; 95% CI, 0.52 to 1.40). The incidence of adverse events did not differ significantly between the two groups. CONCLUSIONS:Vitamin D supplementation did not result in a lower risk of tuberculosis infection, tuberculosis disease, or acute respiratory infection than placebo among vitamin D-deficient schoolchildren in Mongolia. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT02276755.).
Authors: Stephen M Graham; Tahmeed Ahmed; Farhana Amanullah; Renee Browning; Vicky Cardenas; Martina Casenghi; Luis E Cuevas; Marianne Gale; Robert P Gie; Malgosia Grzemska; Ed Handelsman; Mark Hatherill; Anneke C Hesseling; Patrick Jean-Philippe; Beate Kampmann; Sushil Kumar Kabra; Christian Lienhardt; Jennifer Lighter-Fisher; Shabir Madhi; Mamodikoe Makhene; Ben J Marais; David F McNeeley; Heather Menzies; Charles Mitchell; Surbhi Modi; Lynne Mofenson; Philippa Musoke; Sharon Nachman; Clydette Powell; Mona Rigaud; Vanessa Rouzier; Jeffrey R Starke; Soumya Swaminathan; Claire Wingfield Journal: J Infect Dis Date: 2012-03-22 Impact factor: 5.226
Authors: Davaasambuu Ganmaa; Edward Giovannucci; Barry R Bloom; Wafaie Fawzi; Winthrop Burr; Dulguun Batbaatar; Nyamjav Sumberzul; Michael F Holick; Walter C Willett Journal: Am J Clin Nutr Date: 2012-07-03 Impact factor: 7.045
Authors: Christopher T Sempos; Joseph M Betz; Johanna E Camara; Graham D Carter; Etienne Cavalier; Michael W Clarke; Kirsten G Dowling; Ramon A Durazo-Arvizu; Andrew N Hoofnagle; Andy Liu; Karen W Phinney; Kurtis Sarafin; Stephen A Wise; Paul M Coates Journal: J AOAC Int Date: 2017-08-01 Impact factor: 1.913
Authors: Robert Scragg; Alistair W Stewart; Debbie Waayer; Carlene M M Lawes; Les Toop; John Sluyter; Judy Murphy; Kay-Tee Khaw; Carlos A Camargo Journal: JAMA Cardiol Date: 2017-06-01 Impact factor: 14.676
Authors: Omowunmi Aibana; Chuan-Chin Huang; Said Aboud; Alberto Arnedo-Pena; Mercedes C Becerra; Juan Bautista Bellido-Blasco; Ramesh Bhosale; Roger Calderon; Silvia Chiang; Carmen Contreras; Ganmaa Davaasambuu; Wafaie W Fawzi; Molly F Franke; Jerome T Galea; Daniel Garcia-Ferrer; Maria Gil-Fortuño; Barbará Gomila-Sard; Amita Gupta; Nikhil Gupte; Rabia Hussain; Jesus Iborra-Millet; Najeeha T Iqbal; Jose Vicente Juan-Cerdán; Aarti Kinikar; Leonid Lecca; Vidya Mave; Noemi Meseguer-Ferrer; Grace Montepiedra; Ferdinand M Mugusi; Olumuyiwa A Owolabi; Julie Parsonnet; Freddy Roach-Poblete; Maria Angeles Romeu-García; Stephen A Spector; Christopher R Sudfeld; Mark W Tenforde; Toyin O Togun; Rosa Yataco; Zibiao Zhang; Megan B Murray Journal: PLoS Med Date: 2019-09-11 Impact factor: 11.069
Authors: Adrian R Martineau; Robert J Wilkinson; Katalin A Wilkinson; Sandra M Newton; Beate Kampmann; Bridget M Hall; Geoffrey E Packe; Robert N Davidson; Sandra M Eldridge; Zoë J Maunsell; Sandra J Rainbow; Jacqueline L Berry; Christopher J Griffiths Journal: Am J Respir Crit Care Med Date: 2007-04-26 Impact factor: 21.405
Authors: Elisa Nemes; Hennie Geldenhuys; Virginie Rozot; Kathryn T Rutkowski; Frances Ratangee; Nicole Bilek; Simbarashe Mabwe; Lebohang Makhethe; Mzwandile Erasmus; Asma Toefy; Humphrey Mulenga; Willem A Hanekom; Steven G Self; Linda-Gail Bekker; Robert Ryall; Sanjay Gurunathan; Carlos A DiazGranados; Peter Andersen; Ingrid Kromann; Thomas Evans; Ruth D Ellis; Bernard Landry; David A Hokey; Robert Hopkins; Ann M Ginsberg; Thomas J Scriba; Mark Hatherill Journal: N Engl J Med Date: 2018-07-12 Impact factor: 91.245
Authors: George Griffin; Martin Hewison; Julian Hopkin; Rose Anne Kenny; Richard Quinton; Jonathan Rhodes; Sreedhar Subramanian; David Thickett Journal: Clin Med (Lond) Date: 2021-02-16 Impact factor: 2.659
Authors: George Griffin; Martin Hewison; Julian Hopkin; Rose Kenny; Richard Quinton; Jonathan Rhodes; Sreedhar Subramanian; David Thickett Journal: R Soc Open Sci Date: 2020-12-01 Impact factor: 2.963